Replimune stock.

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients. WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, …

Replimune stock. Things To Know About Replimune stock.

Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Friday. Traders purchased 5,463 call options on the stock. This is an increase of approximately 87% ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Nov 24, 2023 · The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ... Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...

Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupItem 1. Description of Registrant’s Securities to be Registered. A description of the common stock of Replimune Group, Inc. (the “Registrant”), par value $0.001 per share, to be registered hereunder is set forth under the caption “Description of capital stock” in the prospectus that constitutes a part of the Registrant’s Registration Statement on Form S …

14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Is Replimune Stock a Buy? The Bottom Line. Replimune has a lot of potential to treat melanomas and other cancerous tumors. If it's proven effective, it can ...Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ...Shares of Replimune have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. ... The stock could also be impacted by negative ...

Get Replimune Group Inc (REPL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Replimune Group Inc stock price live 11.21, this page displays NASDAQ REPL stock exchange data. View the REPL premarket stock price ahead of the market session or assess the after hours quote.

14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Nov 27, 2023 · November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ... Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of ...Oct 15, 2020 · Replimune (NASDAQ: REPL) stock price soared sharply to an all-time high of $46 in Wednesday trading before settling around $36 a share at the end of the session. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%.

Prognosis of advanced and metastatic cutaneous squamous cell carcinoma (CSCC) remains dismal. The anti-PD1 antibody cemiplimab was the first agent approved for the treatment of advanced CSCC. RP1 is an oncolytic virus (HSV-1) that expresses a fusogenic glycoprotein (GALV-GP R-) and granulocyte macrophage colony stimulating factor (GM …15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.Nov 5, 2023 · To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ... Nov 27, 2023 · November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.

Nov 8, 2023 · WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab. Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed ...Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ...Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 …Replimune Group Stock (NASDAQ:REPL), Quotes and News Summary - Benzinga - – –% - – –% - – –% - – –% - – –% - – –% - – –% Replimune Group Inc …RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients. WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune …

Replimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …

Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.

Feb 27, 2023 · Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ... Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ... 37 Salaries (for 31 job titles) • Updated Oct 29, 2023. How much do Replimune employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Our model gets smarter over time as more people …Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupWhy Replimune Stock Is Soaring Today. ... Shares of Replimune Group (REPL-2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The ...Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...Nov 7, 2023 · In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential. Stock Price. $14.2. 2023-11-03. Market Capitalization. $837.7 M. 2023-11-03. Replimune Summary. Company Summary. Overview. Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens ...

Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.Instagram:https://instagram. vuzigoog ipo pricehome loans for ssi recipientsbest mortgage reits Dec 7, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. average price of a rolextesla model 3 federal tax credit 2023 Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class ... nasdaq afrm news View the basic REPL option chain and compare options of Replimune Group, Inc. on Yahoo Finance.Replimune Group, Inc. Common stock $ per share . Replimune Group, Inc. is offering 5,000,000 shares of common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol "REPL." On November 11, 2019, the last reported sale price of our common stock on Nasdaq was $17.21 per share. ...To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...